Circulating cytokines in predicting development of severe acute pancreatitis by Anne Nieminen et al.
Nieminen et al. Critical Care 2014, 18:R104
http://ccforum.com/content/18/3/R104RESEARCH Open AccessCirculating cytokines in predicting development
of severe acute pancreatitis
Anne Nieminen1*, Mikael Maksimow2,3, Panu Mentula1, Lea Kyhälä1, Leena Kylänpää1, Pauli Puolakkainen1,
Esko Kemppainen1, Heikki Repo4 and Marko Salmi2,3,5Abstract
Introduction: Severe acute pancreatitis (AP) is associated with high morbidity and mortality. Early prediction of
severe AP is needed to improve patient outcomes. The aim of the present study was to find novel cytokines or
combinations of cytokines that can be used for the early identification of patients with AP at risk for severe disease.
Methods: We performed a prospective study of 163 nonconsecutive patients with AP, of whom 25 had severe AP
according to the revised Atlanta criteria. Admission serum levels of 48 cytokines and growth factors were determined
using Bio-Plex Pro Human Cytokine Assay 21-plex and 27-plex magnetic bead suspension panels. Admission plasma
levels of C-reactive protein (CRP), creatinine and calcium were measured for comparison. In subgroup analyses, we
assessed the cytokine profiles of patients with severe AP (n = 14) who did not have organ dysfunction (OD) upon
admission (modified Marshall score <2).
Results: Of 14 cytokines elevated in the severe AP group, interleukin 6 (IL-6) and hepatocyte growth factor (HGF)
levels were independent prognostic markers of severe AP. IL-6, HGF and a combination of them predicted severe AP
with sensitivities of 56.0%, 60.0% and 72.0%, respectively, and specificities of 90.6%, 92.8% and 89.9%, respectively. The
corresponding positive likelihood ratio (LR+) values were 5.9, 8.3 and 7.1, respectively. The predictive values of
CRP, creatinine and calcium were comparable to those of the cytokines. In subgroup analyses of patients with
severe AP and without OD upon admission, we found that IL-8, HGF and granulocyte colony-stimulating factor
(G-CSF) levels predicted the development of severe AP, with G-CSF being the most accurate cytokine at a sensitivity
of 35.7%, a specificity of 96.1% and a LR+ of 9.1.
Conclusions: IL-6 and HGF levels upon admission have prognostic value for severe AP which is similar to levels of CRP,
creatinine and calcium. Although IL-6 and HGF, as either single or combined markers, were not perfect in identifying
patients at risk for severe AP, the possibility that combining them with novel prognostic markers other than cytokines
might improve prognostic accuracy needs to be studied. The accuracy of IL-8, HGF and G-CSF levels in predicting
severe AP in patients without clinical signs of OD upon admission warrants larger studies.Introduction
Acute pancreatitis (AP) is usually a mild disease, resolving
within days. Severe AP, as defined according to the revised
Atlanta criteria [1], accounts for about 20% of cases. The
mortality rate in severe AP ranges from 9% to 24% [2,3]
and can be as high as 47% to 69% among patients who
develop multiple organ dysfunction syndrome [4,5].
In AP, premature activation of trypsin within pancreatic
acinar cells causes pancreatic autodigestion, leading to a* Correspondence: anne.k.nieminen@hus.fi
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unless otherwise stated.local inflammatory process. This process is characterized
by the release of pro- and anti-inflammatory cytokines
and other inflammatory mediators, which recruit neutro-
phils, monocytes and lymphocytes into the pancreas. In
severe AP, the local inflammatory process is amplified
and spreads through the circulation throughout the
body, resulting in a systemic inflammatory response
[6,7]. Systemic inflammation is thought to contribute to
the development of organ dysfunction (OD), which may
be transient (<48 hours) or persistent (>48 hours). The
latter is associated with a 35% to 50% mortality rate
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portive care, including early fluid resuscitation, in the
ICU [10,11].
Although levels of a variety of cytokines, determined
upon admission to the hospital, may predict the
course of AP [12-15], no cytokine has proved to be
useful enough to be incorporated into routine clinical
use. Furthermore, to the best of our knowledge, no
attempt has been made to discriminate the predictive
power of cytokines in patients with OD upon admis-
sion from those who are bound to develop OD during
hospitalization.
In this study, we analyzed 48 different cytokines in a
total of 25 patients with severe AP to determine, upon
admission to hospital, novel markers specific for such
patients. We used plasma levels of C-reactive protein
(CRP), creatinine and calcium as conventional biomarkers.
In further analyses of the data, we excluded patients with
modified Marshall scores ≥2, whom, we reasoned, already
had OD upon admission, compared with the respective
patients with modified Marshall scores <2, who developed
OD later during hospitalization.Methods
Patients and definitions
In this prospective study conducted at the Helsinki Uni-
versity Central Hospital between June 2003 and January
2008, we assessed 163 nonconsecutive patients with AP
admitted within 72 hours of the onset of symptoms. Pa-
tients with the signs of chronic pancreatitis were excluded.
AP was diagnosed if two of the following three features
were observed: typical abdominal upper epigastric pain,
serum or plasma amylase level at least three times greater
than the upper limit of normal and characteristic findings
of AP on transabdominal ultrasonography, computed
tomography or magnetic resonance imaging. The severity
of AP was categorized retrospectively according to the
revised Atlanta classification system as mild, moderately
severe (local complication or transient OD) or severe
(persistent OD) [1]. Two patients with severe AP were
referred to Helsinki University Central Hospital because
they needed to be admitted to the ICU.
The Marshall score [16] was calculated according to
the method described by Banks et al. [1] to assess the
presence of OD upon admission. Thus, OD was deemed
to be present if the modified Marshall score was ≥2 for
one of the three organ systems (respiratory, renal or
cardiovascular). A flowchart of the patient distribution
is presented in Figure 1.
All patients, or their next of kin, gave their informed
consent to participate. The Ethics Committee of the
Helsinki University Central Hospital Department of
Surgery approved the study.Samples and cytokine measurements
Serum samples were collected upon admission to the
hospital and stored at −70°C until used for analyses.
Each sample (20 μl) was studied by magnetic bead sus-
pension array using the Bio-Plex Pro Human Cytokine
21- and 27-plex panels (Bio-Rad Laboratories, Hercules,
CA, USA) according to the manufacturer’s instructions
except that the assay reagents were used at half of their
recommended concentrations. The 21-plex panel con-
tains interleukin 1α (IL-1α), IL-2 receptor α (IL-2Rα),
IL-3, IL-12p40, IL-16, IL-18, cutaneous T-cell attracting
chemokine, growth-regulated oncogene α, hepatocyte
growth factor (HGF), interferon α2 (IFN-α2), leukemia
inhibitory factor (LIF), monocyte chemotactic protein 3
(MCP-3), macrophage colony-stimulating factor (M-CSF),
macrophage migration inhibitory factor, monokine induced
by IFN-γ, β-nerve growth factor, stem cell factor, stem cell
growth factor β, stromal cell–derived factor 1α, tumor ne-
crosis factor β (TNF-β) and TNF-related apoptosis inducing
ligand. The 27-plex contains IL-1β, IL-1 receptor antagonist,
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-
13, IL-15, IL-17A, basic fibroblast growth factor, eotaxin,
granulocyte colony-stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), IFN-γ,
IFN-γ-induced protein 10, monocyte chemotactic protein 1
(MCP-1), macrophage inflammatory protein 1α (MIP-1α),
MIP-1β, platelet-derived growth factor BB, regulated
on activation, normal T cell expressed and secreted (that
is, RANTES), TNF-α and vascular endothelial growth
factor. The samples were analyzed using the Bio-Plex 200
System, and the results were calculated using Bio-Plex
Manager 6.0 software (Bio-Rad Laboratories).
No measurable values for IFN-α2 were obtained from
any sample, and thus this cytokine was excluded from data
analyses. Also, the majority of the values for LIF, eotaxin,
GM-CSF, IL-1α, IL-3, IL-12p40, IL-15 and TNF-β were
below the detectable limit, and therefore these cytokines
were scored on a dichotomous scale of detectable or un-
detectable value. The persons doing the cytokine measure-
ments were unaware of the clinical status of the patients.
Plasma levels of CRP (normal reference range <10 mg/L),
creatinine (50 to 90 μmol/L) and calcium (2.15 to 2.51
mmol/L) were determined in accordance with our hospital’s
laboratory routine.
Statistical analysis
Statistical analysis was performed using IBM SPSS ver-
sion 19 statistical software (SPSS, Chicago, IL, USA). The
results are given as medians with ranges and interquartile
ranges (IQR). Spearman’s rank correlation was used to test
correlations between two continuous variables. For uni-
variate analysis, comparisons between groups were made
using the Mann–Whitney U test. The level of significance
was adjusted using the Bonferroni method by dividing the
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Figure 1 Patient classifications according to modified Marshall score [20] and revised Atlanta criteria [1] upon admission. MMS,
Modified Marshall score.
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tests. After univariate analysis, parameters were entered
into multivariate analysis, and logistic regression analysis
was performed to identify independent markers predictive
of persistent OD. In the post hoc analysis, we determined
clinically optimal cutoff values for each cytokine using
receiver operating characteristic (ROC) curves, with cor-
responding sensitivities, specificities, positive likelihood
ratios (LR+), negative likelihood ratios (LR−) and diagnos-




severe AP (n = 138)
P-val
Men 120 (73.6) 96 (69.6) 0.006
Age, years 48 (18 to 87) 49 (18 to 87) NS
Etiology
Alcohol 113 (69.3) 91 (65.9) 0.028
Biliary 35 (21.5) 34 (24.6) 0.021
Other cause 11 (6.7) 9 (6.5) NS
Idiopathic 4 (2.5) 4 (2.9) NS
Onset of symptoms, hr 24 (1 to 72) 24 (1 to 72) NS
C-reactive protein, mg/L 19 (3 to 435) 16 (3 to 426) 0.002
Creatinine, μmol/L 64 (31 to 1086) 62 (31 to 313) <0.00
Calcium, mmol/L 2.2 (1.27 to 2.73) 2.23 (1.27 to 2.73) <0.00
Length of hospital stay, days 6 (1 to 93) 5 (1 to 41) <0.00
Mechanical ventilation 25 (15.3) 2 (1.4) <0.00
Renal replacement therapy 16 (9.8) 0 <0.00
OD within 24 hours 30 (18.4) 10 (7.2) <0.00
OD on days 1 to 7 5 (3.1) 0 <0.00
Mortality 8 (4.9) 1 (0.7) 0.014
aAP, Acute pancreatitis; MMS, Modified Marshall score; NS, Not significant; OD, orga
severe AP (n = 138) and severe AP (n = 25). The severe AP group is categorized int
median (range) or n (%).The DOR is the ratio of the odds of positive test results
(OD) among patients with OD to the odds of a positive
test result (OD) among the patients without OD. The
higher the value, the better the discriminatory test per-
formance is [18]. The clinically optimal cutoff value was
defined as the point on the curve where the number or
false positives is as low as possible (specificity ≥90%),
with the maximum sensitivity, to avoid overtreatment
of patients in the ICU. Areas under the ROC curve
were also calculated.ueb Severe AP (n = 25)
All (N = 25) MMS <2 (n = 14) P-value MMS ≥2 (n = 11)
24 (96.0) 13 (92.9) NS 11 (100.0)
43 (29 to 81) 41 (29 to 81) NS 51 (29 to 69)
22 (88.0) 11 (78.6) NS 11 (100)
1 (4.0) 1 (7.1) NS 0
2 (8.0) 2 (14.3) NS 0
0 0 NS 0
24 (3 to 72) 18 (3 to 48) <0.001 48 (24 to 72)
94 (3 to 435) 30 (3 to 229) <0.001 294 (22 to 435)
1 92 (47 to 1086) 68 (47 to 147) <0.001 248 (92 to 1086)
1 1.86 (1.39 to 2.30) 2.04 (1.49 to 2.30) 0.013 1.67 (1.39 to 2.17)
1 26 (1 to 93) 28 (1 to 93) NS 17 (1 to 49)
1 23 (92.0) 13 (92.9) NS 10 (90.9)
1 16 (64.0) 7 (50.0) NS 9 (81.8)
1 20 (80.0) 9 (64.3) NS 11 (100)
1 5 (20.0) 5 (37.5) NS 0 (0)
7 (28.0) 2 (14.3) NS 5 (45.5)
n dysfunction. bSignificance of the difference between mild or moderately
o two subgroups: admission modified Marshall Score <2 or ≥2. Data are
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Patients
The characteristics of the patients are shown in Table 1.
The severity of AP was classified as mild in 103 patients
(63%), moderately severe in 35 patients (17%) and severe
in 25 patients (15%). All of the patients with severe AP
developed persistent OD and required invasive mechan-
ical ventilation and/or renal replacement therapy.
OD was present upon admission in 21 patients (13%).
Ten of these cases were transient OD, which responded
rapidly to treatment and resolved within 48 hours. In
these cases, the severity of AP was classified as moderately
severe. Eleven patients with severe AP had OD upon ad-
mission, and another nine patients developed OD within
24 hours after admission. Five patients developed OD
within 1 to 7 days after admission. There were no cases of
new-onset OD after the first week of treatment.
The overall mortality rate was 4.9%. Seven (28%) of
the twenty-five patients with severe AP died. Two of
them were not admitted to the ICU because of their old
age and comorbidities, and they died within 48 hours.
One patient with moderately severe AP died as a result
of carbon dioxide retention.
Cytokine profiles of patients with severe acute pancreatitis
The levels of 14 of 47 cytokines measured were signifi-
cantly higher in the severe AP group than in the mild and
moderately severe AP groups (P < 0.001 after BonferroniTable 2 The 14 cytokines that differed between mild or mode
acute pancreatitis patientsa
All patients (N = 163)
Cytokines Mild or moderately
severe AP (n = 138)
P-valueb Severe (n = 25)
G-CSF 119.7 (66.6-198.2) <0.001 260.2 (132.5 to 1011.8)
GRO-α 58.8 (35.7-92.3) <0.001 128.2 (98.4 to 169.1)
HGF 1055.5 (764.7-1730.6) <0.001 3613.0 (2055.3 to 6348.
IL-2Rα 214.2 (150.6-316.7) <0.001 483.3 (385.6 to 673.3)
IL-6 59.7 (15.3-202.1) <0.001 428.9 (138.5 to 1796.3)
IL-8 26.6 (19.3-41.9) <0.001 82.4 (46.4 to 115.6)
IL-18 139.6 (91.6-187.1) <0.001 202.8 (151.8 to 305.4)
LIFc 0 (0) <0.001 1 (0 to 1)
M-CSF 14.5 (8.1-28.1) <0.001 40.2 (18.6 to 68.6)
MCP-1 49.0 (21.0-111.2) <0.001 125.0 (64.6 to 199.6)
MCP-3 17.4 (0.57-53.6) <0.001 54.58 (24.3 to 98.7)
β-NGF 5.79 (3.65-9.1) <0.001 11.3 (7.4 to 15.9)
SCF 114.1 (85.2-147.0) 0.0008 155.8 (109.2 to 256.0)
SDF-1α 87.6 (53.5-151.5) <0.001 163.6 (104.4 to 226.3)
aβ-NGF, β-nerve growth factor; G-CSF, granulocyte colony-stimulating factor; GRO-α
IL-1Ra, Interleukin 1 receptor antagonist; IL-2Rα, Interleukin 2 receptor α; SDF, strom
protein; M-CSF, Macrophage colony-stimulating factor; SDF, Stromal derived factor;
NS, not significant. bLevel of significance is defined as P < 0.001 (Bonferroni-adjuste
expressed as median (IQR).adjustment) (Table 2). The corresponding differences in
the levels of the other 33 cytokines were not significant
(Table 3).
By stepwise forward logistic regression analysis of
the 14 cytokines, we identified IL-6 (P = 0.006) and
HGF (P < 0.001) as independent prognostic markers of
severe AP. Many of the other 14 cytokines (M-CSF,
HGF, IL-8, MCP-1 and G-CSF) had a strong positive
Spearman’s correlation with IL-6 (r > 0.6) (Table 4).
M-CSF, IL-8, MCP-1 and G-CSF did not improve the
explanatory power of the regression model and thus
were excluded from the stepwise analysis.
IL-6 and HGF levels predicted severe AP with sensitiv-
ities of 48.0% and 60.0%, respectively, and specificities of
93.5% and 92.8%, respectively (Table 5). In the combined
regression model of IL-6 and HGF, sensitivity was im-
proved to 72.0% and specificity remained high at 89.9%.
The LR+ values for IL-6, HGF and the combined model
were 7.4, 8.3 and 7.1, respectively, and the DOR values
were 13.2, 19.8 and 22.8, respectively. None of the differ-
ences between IL-6, HGF and the combined model were
statistically significant (Table 5). Additional file 1 shows
the diagnostic performance of all of the 14 cytokines
that could differentiate mild or moderately severe AP
from severe AP.
The discriminatory power of plasma calcium <1.91
mmol/L, creatinine >141 μmol/L and CRP >227 mg/L
was comparable to that of IL-6 and HGF (Table 5).rately severe acute pancreatitis patients and severe
Admission MMS <2 (n = 142)
Mild or moderately
severe AP (n = 128)
P-valueb Severe AP (n = 14)
118.41 (66.6 to 174.3) 0.0007 234.0 (151.2 to 531.1)
54.5 (33.2 to 82.5) 0.002 (NS) 118.5 (62.4 to 158.4)
8) 989.6 (753.6 to 1501.6) <0.001 2202.6 (1554.3 to 3305.5)
209.5 (145.5 to 290.4) 0.0015 (NS) 449.7 (228.1 to 504.3)
49.9 (14.7 to 185.6) 0.0013 (NS) 234.5 (66.2 to 1931.3)
25.41 (18.0 to 37.6) <0.001 59.7 (32.0 to 102.8)
131.5 (90.7 to 181.5) 0.062 (NS) 162.4 (135.3 to 201.6)
0 (0) 0.002 (NS) 1 (0 to 1)
12.4 (5.5 to 21.5) 0.007 (NS) 28.7 (12.2 to 52.0)
47.6 (30.0 to 100.6) 0.032 (NS) 92.1 (36.3 to 185.2)
16.3 (0.2 to 47.9) 0.006 (NS) 52.0 (16.5 to 102.1)
5.5 (3.4 to 8.5) 0.007 (NS) 10.4 (4.5 to 15.5)
111.6 (82.0 to 143.3) 0.012 (NS) 148.5 (107.3 to 218.9)
86.8 (52.8 to 148.5) 0.010 (NS) 171.3 (85.1 to 234.8)
, Growth-related oncogene α; HGF, Hepatocyte growth factor; IL, Interleukin;
al derived factor; LIF, Leukemia inhibitory factor; MCP, Monocyte chemotactic
SCF, Stem cell factor; SDF, Stromal cell–derived factor IQR, interquartile range;
d). c0 = Undetectable value, 1 = Detectable value. Cytokine levels (pg/ml) are
Table 3 Levels of 33 cytokines showing no significant difference between mild or moderately severe and severe acute
pancreatitisa
Cytokines Mild or moderately severe AP (n = 138) P-valueb Severe AP (n = 25)
CTACK 993.1 (746.4 to 1,556.1) 0.033 (NS) 693.3 (652.5 to 1,150.6)
Eotaxinc 1 (0 to 1) 0.133 (NS) 1 (0 to 1)
FGF 25.9 (8.6 to 44.6) 0.123 (NS) 19.4 (0.4 to 35.2)
GM-CSFc 0 (0) 0.663 (NS) 0 (0 to 1)
IFN-γ 99.5 (50.7 to 151.0) 0.772 (NS) 82.4 (50.9 to 149.5)
IP-10 379.3 (244.5 to 594.0) 0.475 (NS) 446.2 (222.6 to 825.3)
IL-1αc 0 (0 to 1) 0.473 (NS) 1 (0 to 1)
IL-1β 1.9 (0.8 to 3.0) 0.961 (NS) 1.9 (0.5 to 3.4)
IL-1Ra 121.1 (64.8 to 260.0) 0.131 (NS) 202.6 (70.9 to 669.8)
IL-2 7.6 (2.2 to 13.4) 0.796 (NS) 6 to 7 (1.7 to 12.9)
IL-3c 0 (0) 0.008 (NS) 0 (0 to 1)
IL-4 5.1 (2.6 to 7.5) 0.261 (NS) 3.8 (2.3 to 6.4)
IL-5 2.7 (1.6 to 4.1) 0.091 (NS) 1.8 (1.0 to 3.4)
IL-7 5.9 (3.9 to 10.5) 0.482 (NS) 5.2 (3.9 to 9.4)
IL-9 19.5 (7.3 to 37.8) 0.410 (NS) 16.1 (1.7 to 38.7)
IL-10 8.2 (3.9 to 17.7) 0.012 (NS) 15.8 (6.2 to 42.3)
IL-12p70 18.7 (11.2 to 40.4) 0.442 (NS) 15.5 (9.0 to 36.5)
IL-12p40c 0 (0) 0.691 (NS) 0 (0)
IL-13 7.2 (3.9 to 13.5) 0.249 (NS) 6.5 (2.6 to 12.1)
IL-15c 0 (0) 0.018 (NS) 0 (0 to 1)
IL-16 220.2 (99.9 to 786.8) 0.120 (NS) 341.3 (157.2 to 980.1)
IL-17A 79.8 (33.2 to 155.9) 0.084 (NS) 45.8 (9.2 to 98.4)
MIP-1α 6.2 (3.7 to 8.0) 0.215 (NS) 4.6 (2.4 to 7.1)
MIP-1β 67.1 (42.6 to 90.2) 0.830 (NS) 63.6 (40.1 to 95.8)
MIF 695.8 (348.5 to 1,553.9) 0.004 (NS) 1461.2 (713.4 to 4,529.4)
MIG 1,415.5 (821.0 to 2,348.2) 0.021 (NS) 2,147.5 (1,257.4 to 4,268.7)
PDGF-BB 1,183.6 (360.4 to 2,475.2) 0.063 (NS) 583.3 (207.8 to 1,427.3)
RANTES 2,905.6 (1,110.3 to 4,511.1) 0.093 (NS) 1,877.2 (787.5 to 3,090.9)
SCGF-β 31452.4 (21610.3 to 46978.0) 0.004 (NS) 47129.9 (30743.1 to 56343.2)
TRAIL 57.4 (33.3 to 92.0) 0.042 (NS) 84.8 (51.8 to 122.7)
TNF-α 20.8 (10.3 to 31.9) 0.730 (NS) 18.2 (9.7 to 31.5)
TNF-βc 0 (0 to 1) 0.187 (NS) 0 (0)
VEGF 29.9 (17.7 to 71.1) 0.436 (NS) 23.6 (17.4 to 64.2)
aAP, Acute pancreatitis; CTACK, Cutaneous T-cell attracting chemokine; FGF, Basic fibroblast growth factor; GM-CSF, Granulocyte-macrophage colony-stimulating
factor; IFN, Interferon; IL, Interleukin; IL-1Ra, Interleukin 1 receptor antagonist; IP-10, Interferon-γ-induced protein 10; VEGF, vascular endothelial growth factor; MIF,
Macrophage migration inhibitory factor; MIG, Monokine induced by interferon γ; MIP, Macrophage inflammatory protein; VEGF, vascular endothelial growth factor;
PDGF-BB, Platelet-derived growth factor, two BB chains; RANTES, Regulated on activation, normal T cell expressed and secreted; SCGF-β, Stem cell growth factor β;
TNF, Tumor necrosis factor; TRAIL, Tumor necrosis factor–related apoptosis-inducing ligand; VEGF, Vascular endothelial growth factor IQR, interquartile range; NS, Not
significant. bLevel of significance is defined as P < 0.001 (Bonferroni-adjusted). c0 = Undetectable value, 1 = Detectable value. Data are median (IQR).
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the logistic regression analysis with IL-6 and HGF, cal-
cium was also able to predict severe AP independently
(P = 0.023), as were IL-6 (P = 0.025) and HGF (P = 0.027),
but creatinine (P = 0.86) and CRP (P = 0.45) were not.
The ROC curves for the logistic regression model of
IL-6 and HGF and that for CRP are presented inFigure 2, and their clinically optimal cutoff points are
listed in Table 5.
Predicting severe acute pancreatitis in patients with
modified Marshall score <2 upon admission
In the patients who developed persistent OD after admis-
sion to the hospital (n = 14), compared with patients who
Table 4 Cytokines showing strong correlation with
interleukin 6a






aG-CSF, Granulocyte colony-stimulating factor; HGF, Hepatocyte growth factor;
IL, Interleukin; MCP, Monocyte chemotactic protein.
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http://ccforum.com/content/18/3/R104did not (n = 128), the levels of IL-8, HGF and G-CSF
were significantly higher (P < 0.001, Bonferroni-adjusted)
(Table 2). We did not perform multivariate analysis in
this subgroup, owing to the low number of patients.
We therefore determined how many of these 14 OD
patients could be identified using the same clinically
optimal cutoff points that we used earlier for the whole
patient cohort (Table 5). G-CSF correctly predicted
severe AP in 5 of 14 patients (Table 6). IL-8 detected
one patient, and HGF identified two additional patients.
Thus, the combination of these three cytokines detected
eight of fourteen OD patients. The diagnostic perform-
ance of each cytokine (IL-8, HGF and G-CSF) and that of
the combination are presented in Table 7.
In the subgroup of patients who developed persistent
OD after admission, calcium had a sensitivity of 36.4%, a
specificity of 94.3%, a LR+ value of 6.4 and a DOR value
of 9.5. These values were similar to the respective values
for G-CSF (Table 6). The sensitivity of CRP and creatin-
ine each was 7.1%, indicating poor performance in
predicting OD. The ROC curves of G-CSF and CRP
are presented in Figure 3.
Predicting severe acute pancreatitis in patients with
admission modified Marshall scores ≥2
When comparing the levels of 14 cytokines in the
patients with transient OD (n = 10) or persistent OD
(n = 11), we found that the levels of HGF were higherTable 5 Diagnostic performances of interleukin 6 and hepato
predicting severe acute pancreatitis in all patients (N = 163)a
Predictive marker with
optimal cutoff point
AUC Sensitivity (%) Spec
IL-6 (>501.6 pg/ml) 0.81 (0.72 to 0.90) 48.0 (30.0 to 66.5) 93.5
HGF (>3,020.1 pg/ml) 0.87 (0.81 to 0.94) 60.0 (40.7 to 0.77) 92.8
IL-6 + HGF 0.89 (0.82 to 0.96) 72.0 (52.4 to 85.7) 89.9
CRP (>227 mg/L) 0.692 (0.57 to 0.82) 40.0 (23.4 to 59.3) 93.5
Creatinine (>141 μmol/L) 0.76 (0.65 to 0.88) 40.0 (23.4 to 59.3) 96.3
Calcium (<1.91 mmol/L) 0.81 (0.70 to 0.91) 57.9 (36.3 to 76.9) 93.2
aIL, interleukin; CRP, C-reactive protein; IL, interleukin; HGF, Hepatocyte growth facto
LR−, Negative likelihood ratio; LR+, Positive likelihood ratio; 95% confidence intervain the patients with persistent OD (P = 0.007); how-
ever, the difference was not significant after we applied
the Bonferroni correction. IL-6 and IL-8 had P-values
of 0.067 and 0.057, respectively, and the rest of the
cytokines had P-values >0.1.
Discussion
The results of our present study show that the levels of
14 of 47 cytokines were significantly higher in the severe
AP group than in the patients with mild or moderately
severe AP. Regression analysis, however, revealed that
only IL-6 and HGF were independent predictive markers
of severe AP. Both IL-6 and HGF are multifunctional
cytokines that play many roles in inflammation, and the
serum levels of these cytokines reflect the magnitude of
the inflammatory response.
IL-6 is a proinflammatory cytokine released by macro-
phages in response to tissue injury, and it stimulates the
synthesis of acute phase proteins (for example, CRP) in
the liver. HGF stimulates mitogenesis, cell motility and
matrix invasion, and thus it has a central role in angio-
genesis, tumorigenesis and tissue regeneration [19]. Both
IL-6 [12,20] and HGF [21,22] have been demonstrated
to have prognostic value for AP upon admission. These
studies, together with the results of the present study,
indicating LR+ values 7.4 and 8.3 for IL-6 and HGF,
respectively, for predicting severe AP, thus give credence
to the view etc., thus giving credence to the view that
single cytokines such as IL-6 and HGF may not be per-
fect predictors of severe AP. Our results also show that
the LR+ value for the combination of IL-6 and HGF was
7.1, indicating that combining the cytokines did not im-
prove their predictive accuracy for severe AP. One reason
for this may be the strong Spearman’s correlation between
IL-6 and HGF, and, indeed, with many other cytokines
(Table 4). Moreover, the sensitivities, specificities and
LR+ were determined using post hoc analysis in which
the cutoff points were set in the same population. If the
analyses had been done prospectively with preset cutoff
values, the predictive power of biomarkers would mostcyte growth factor and conventional markers in
ificity (%) LR+ LR− DOR
(88.1 to 96.5) 7.4 (3.5 to 15.6) 0.56 (0.38 to 0.81) 13.2 (4.7 to 37.3)
(87.1 to 96.0) 8.3 (4.2 to 16.3) 0.43 (0.27 to 0.70) 19.2 (6.9 to 53.6)
(83.7 to 93.9) 7.1 (4.1 to 12.3) 0.31 (0.17 to 0.59) 22.8 (8.1 to 64.0)
(88.0 to 96.5) 6.1 (2.8 to 13.6) 0.64 (0.47 to 0.89) 9.6 (3.4 to 27.2)
(91.7 to 98.4) 10.9 (4.1 to 29.1) 0.62 (0.45 to 0.86) 17.5 (5.3 to 57.9)
(87.6 to 96.4) 8.5 (4.1 to 17.8) 0.45 (0.27 to 0.77) 18.8 (6.0 to 58.4)
r; IL, Interleukin; AUC, Area under curve; DOR, Diagnostic odds ratio;
ls are given in parentheses.

















Figure 2 Receiver operating characteristic curves of C-reactive protein and interleukin 6 plus hepatocyte growth factor for prediction
of severe acute pancreatitis in the entire acute pancreatitis patient cohort (N = 163). Boxes indicate clinically optimal cutoff points used to
calculate the sensitivity and specificity of each biomarker listed in Table 5. CRP, C-reactive protein; HGF, Hepatocyte growth factor; IL, Interleukin.
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http://ccforum.com/content/18/3/R104probably have been even lower. Taken together, the results
suggest that none of the cytokines alone or combinations
of them would be useful in clinical practice, which would
require LR+ values >10.
In agreement with previous studies [23-25], our results
show that many severe AP patients already have OD
upon presentation. Consequently, to find true prognostic
markers, such patients should be excluded from furtherTable 6 Performance of biomarkers to predict severe acute p
Score <2 (N = 14)a
Severe AP
patients
IL-8 >88.1 pg/ml HGF >3,020.1 pg/ml G-CSF >477.7 pg/m
1 − − −
2 − + +
3 − − −
4 + − −
5 − + +
6 − + −
7 − − −
8 − − −
9 − − −
10 + − +
11 − − −
12 + − +
13 − + −
14 + − +
aAP, Acute pancreatitis; CRP, C-reactive protein; G-CSF, Granulocyte colong-stimulat
point (except for calcium below cutoff point). −, Value below cutoff point (except foanalysis. We did so in the subgroup analysis with a lim-
ited number of severe AP patients (n = 14). When we
compared the severe AP groups with admission modified
Marshall scores <2 or ≥2, we found that the latter group
had had symptoms significantly longer and had significantly
higher CRP and creatinine levels upon admission, but
otherwise no other clinical marker or symptom differed
between the groups. In the group of severe AP patientsancreatitis in patients with admission modified Marshall















ing factor; HGF, Hepatocyte growth factor; IL, Interleukin. +, Value above cutoff
r calcium above cutoff point). bMissing data.
Table 7 Diagnostic performances of biomarkers markers in predicting severe acute pancreatitis in patients with
admission modified Marshall score <2 (N = 142)a
Predictive marker and
optimal cutoff point
AUC Sensitivity (%) Specificity (%) LR+ LR− DOR
IL-8 (>88.1 pg/ml) 0.79 (0.68 to 0.90) 25.6 (11.7 to 54.7) 95.3 (90.2 to 97.8) 6.1 (2.0 to 19.0) 0.75 (0.54 to 1.05) 8.1 (2.0 to 33.6)
HGF (>3,020.1 pg/ml) 0.83 (0.73 to 0.92) 28.6 (11.7 to 54.7) 95.3 (0.90 to 97.8) 6.1 (2.0 to 19.0) 0.75 (0.54 to 1.05) 8.1 (2.0 to 33.6)
G-CSF (>477.7 pg/ml) 0.78 (0.65 to 0.90) 35.6 (16.3 to 61.2) 96.1 (91.2 to 98.3) 9.1 (3.0 to 27.7) 0.67 (0.45 to 0.99) 13.7 (3.3 to 56.1)
CRP (>227 mg/L) 0.54 (0.37 to 0.70) 7.1 (1.3 to 31.5) 95.3 (90.2 to 97.8) 1.5 (0.2 to 11.8) 0.97 (0.2 to 11.8) 1.6 (0.2 to 14.0)
Creatinine (>141 μmol/L) 0.62 (0.45 to 0.79) 7.1 (1.3 to 31.5) 99.2 (95.7 to 99.9) 9.1 (0.6 to 37.2) 0.94 (0.91 to 1.08) 9.7 (0.57 to 164.2)
Calcium (<1.91 mmol/L) 0.74 (0.60 to 0.88) 36.4 (15.2 to 64.6) 94.3 (88.7 to 97.2) 6.4 (2.2 to 18.5) 0.68 (0.43 to 1.06) 9.5 (2.2 to 40.2)
G-CSF + IL-8 + HGF 57.1 (32.6 to 78.6) 90.6 (84.3 to 94.6) 6.1 (3.0 to 12.3) 0.47 (0.26 to 0.87) 12.9 (3.8 to 43.4)
aIL, Interleukin; CRP, C-reactive protein; IL, interleukin; G-CSF, Granulocyte colony-stimulating factor; HGF, Hepatocyte growth factor; IL, Interleukin; AUC, Area under
the curve; DOR, Diagnostic odds ratio; LR−, Negative likelihood ratio; LR+, Positive likelihood ratio. 95% confidence intervals are given in parentheses.
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http://ccforum.com/content/18/3/R104who presented with modified Marshall scores <2, HGF, as
well as also IL-8 and G-CSF, measured upon admission
predicted later development of OD. The combination of
HGF, G-CSF and IL-8 identified 8 of 14 of these severe AP
patients. Thus, in 6 of 14 patients, none of these cytokines
were raised above the cutoff level, although there was no
difference in the clinical course of the disease. The reason
for this may derive from variations in immune responses
between individuals, the kinetics of the cytokines and/or
the phase of AP. This raises the question whether combin-
ing cytokines with other, non-cytokine-related prognostic













Figure 3 Receiver operating characteristic curves of granulocyte colo
severe acute pancreatitis in patients with admission modified Marsha
used to calculate the sensitivity and specificity of each biomarker given in
factor; MMS, Modified Marshall score.AP. Several markers, other than cytokines, have been
found to be of prognostic value in OD associated with
systemic inflammation [26-30]. Furthermore, novel bio-
markers will most probably be discovered by means of
systems biology, as reviewed by Skibsted et al. [31].
The crucial question in clinical practice is how to dis-
tinguish, upon admission to the hospital, those patients
with transient OD from those with persistent OD. At
present, no means of identifying such patients exist. In
our present study, the limited number of persistent OD
patients had higher levels of HGF, IL-6 and IL-8, but
the differences were not statistically significant. WhetherG-SCF
CRP
               0,8               1,0 
ity
MMS<2 patients
ny-stimulating factor and C-reactive protein for prediction of
ll scores <2 (N = 142). Boxes indicate clinically optimal cutoff points
Table 7. CRP, C-reactive protein; G-CSF, Granulocyte colony-stimulating
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http://ccforum.com/content/18/3/R104these cytokines, as individual or combined markers, can
aid in distinguishing between transient and persistent OD
needs to be studied in a larger number of OD patients
upon admission to the hospital.
Although no specific treatment for AP exists so far,
concomitantly with better understanding of the underlying
pathophysiology, immunomodulatory treatment has be-
come a matter of interest. However, many patients already
have OD upon admission [23]. In addition, AP patients
may develop immune suppression rapidly [32]. In such
patients, anti-inflammatory therapy may be detrimental.
In some patients, immune suppression is confined mainly
to the circulation and the inflammatory stage proceeds in
other body compartments, such as the lungs [33]. In this
complex setting, the determination of immune inflamma-
tory status may aid in the selection of appropriate immune-
modulating therapy to prevent or alleviate OD [34].
Conclusions
We analyzed the levels of 48 cytokines in 163 patients
with AP upon admission to the hospital. IL-6 and HGF
were independent predictive markers of severe AP; how-
ever, neither cytokine nor the combination of them was
perfect in identifying AP patients at risk for severe
disease. In fact, the results are similar to those for CRP,
creatinine and calcium. IL-8, HGF and G-CSF levels
could be used to predict severe AP in patients without
clinical signs of OD upon admission. To the best of our
knowledge, this study is the largest to date with regard
to the number of cytokines screened in a group of AP
patients. The possibility that combining cytokines with
prognostic markers other than cytokines improves the
prediction of severe AP warrants further studies.
Key messages
 The levels of 14/47 cytokines upon admission to the
hospital were higher in patients with severe AP than
in those with mild or moderately severe AP.
 IL-6 and HGF were independent predictors of
severe AP.
 The predictive value of IL-6 and HGF was comparable
to that of CRP, creatinine and calcium.
 Many patients who will develop severe AP, did not
have signs of OD upon admission to hospital.
 IL-8, HGF and G-CSF is able to predict severe AP in
patients without clinical signs of OD at the time of
hospital admission.Additional file
Additional file 1: Diagnostic performances of the 14 cytokines that
could differentiate mild or moderately severe AP from severe AP.Abbreviations
AP: Acute pancreatitis; AUC: Area under the curve; β-NGF: β nerve growth
factor; CRP: C-reactive protein; CTACK: Cutaneous T-cell attracting chemokine;
DOR: Diagnostic odds ratio; FGF: Basic fibroblast growth factor; G-CSF: Granulocyte
colony-stimulating factor; GM-CSF: Granulocyte-macrophage colony-stimulating
factor; HGF: Hepatocyte growth factor; IFN: Interferon; IL: Interleukin;
IL-1Ra: Interleukin 1 receptor antagonist; IL-2Rα: Interleukin 2 receptor α;
IP-10: Interferon-γ-induced protein 10; LIF: Leukemia inhibitory factor;
LR: Likelihood ratio; MCP: Monocyte chemotactic protein; M-CSF: Macrophage
colony-stimulating factor; MIF: Macrophage migration inhibitory factor;
MIG: Monokine induced by interferon γ; MIP: Macrophage inflammatory protein;
OD: Organ dysfunction; PDGF-BB: Platelet-derived growth factor, two BB chains;
RANTES: Regulated on activation, normal T cell expressed and secreted;
ROC: Receiver operating characteristic curve; SCF: Stem cell factor; SCGF-β: Stem
cell growth factor β; SDF: Stromal cell–derived factor; TNF: Tumor necrosis
factor; TRAIL: Tumor necrosis factor–related apoptosis-inducing ligand;
VEGF: Vascular endothelial growth factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AN and LKyh collected clinical data and participated in data analyses. AN
and HR drafted the manuscript. MM analyzed the cytokine levels. PM was a
supervisor of the data analyses and participated in designing the study. LKyl,
EK and PP participated in designing and coordinating the study and provided
supervision. MS and HR designed and supervised the study. All authors critically
revised the manuscript and read and approved the final version.
Acknowledgements
Mrs. Teija Kanasuo is thanked for her excellent technical assistance. The work
was supported by the Martti I Turunen Foundation and the Emil Aaltonen
Foundation (to AN) and by the Academy of Finland (to MS).
Author details
1Department of Surgery, Helsinki University Central Hospital, POB 340, Helsinki
00029 HUS, Finland. 2MediCity Research Laboratory, University of Turku,
Tykistönkatu 6A, 20520 Turku, Finland. 3Department of Medical Microbiology and
Immunology, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland.
4Department of Bacteriology and Immunology, Haartman Institute, University of
Helsinki, PO Box 21, Helsinki 00014, Finland. 5National Institute for Health and
Welfare, Turku, Finland.
Received: 18 February 2014 Accepted: 1 May 2014
Published: 21 May 2014
References
1. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG,
Vege SS, Acute Pancreatitis Classification Working Group: Classification of
acute pancreatitis—2012: revision of the Atlanta classification and
definitions by international consensus. Gut 2013, 62:102–111.
2. Halonen KI, Leppaniemi AK, Puolakkainen PA, Lundin JE, Kemppainen EA,
Hietaranta AJ, Haapiainen RK: Severe acute pancreatitis: prognostic factors
in 270 consecutive patients. Pancreas 2000, 21:266–271.
3. Gloor B, Müller CA, Worni M, Martignoni ME, Uhl W, Büchler MW: Late
mortality in patients with severe acute pancreatitis. Br J Surg 2001,
88:975–979.
4. McKay CJ, Buter A: Natural history of organ failure in acute pancreatitis.
Pancreatology 2003, 3:111–114.
5. Vege SS, Gardner TB, Chari ST, Munukuti P, Pearson RK, Clain JE, Petersen BT,
Baron TH, Farnell MB, Sarr MG: Low mortality and high morbidity in
severe acute pancreatitis without organ failure: a case for revising the
Atlanta classification to include “moderately severe acute pancreatitis.”.
Am J Gastroenterol 2009, 104:710–715.
6. Norman J: The role of cytokines in the pathogenesis of acute
pancreatitis. Am J Surg 1998, 175:76–83.
7. Kylänpää ML, Repo H, Puolakkainen PA: Inflammation and
immunosuppression in severe acute pancreatitis. World J Gastroenterol
2010, 16:2867–2872.
Nieminen et al. Critical Care 2014, 18:R104 Page 10 of 10
http://ccforum.com/content/18/3/R1048. Buter A, Imrie CW, Carter CR, Evans S, McKay CJ: Dynamic nature of early
organ dysfunction determines outcome in acute pancreatitis. Br J Surg
2002, 89:298–302.
9. Johnson CD, Abu-Hilal M: Persistent organ failure during the first week as
a marker of fatal outcome in acute pancreatitis. Gut 2004, 53:1340–1344.
10. Banks PA, Freeman ML: Practice guidelines in acute pancreatitis. Am J
Gastroenterol 2006, 101:2379–2400.
11. Forsmark CE, Baillie J: AGA Institute technical review on acute
pancreatitis. Gastroenterology 2007, 132:2022–2044.
12. Leser HG, Gross V, Scheibenbogen C, Heinisch A, Salm R, Lausen M,
Rückauer K, Andreesen R, Farthmann EH, Schölmerich J: Elevation of serum
interleukin-6 concentration precedes acute-phase response and reflects
severity in acute pancreatitis. Gastroenterology 1991, 101:782–785.
13. Brivet FG, Emilie D, Galanaud P: Pro- and anti-inflammatory cytokines during
acute severe pancreatitis: an early and sustained response, although
unpredictable of death. Crit Care Med 1999, 27:749–755.
14. Chen CC, Wang SS, Lee FY, Chang FY, Lee SD: Proinflammatory cytokines
in early assessment of the prognosis of acute pancreatitis. Am J
Gastroenterol 1999, 94:213–218.
15. Mayer J, Rau B, Gansauge F, Beger HG: Inflammatory mediators in human
acute pancreatitis: clinical and pathophysiological implications. Gut 2000,
47:546–552.
16. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ:
Multiple organ dysfunction score: a reliable descriptor of a complex
clinical outcome. Crit Care Med 1995, 23:1638–1652.
17. Newcombe RG: Two-sided confidence intervals for the single proportion:
comparison of seven methods. Stat Med 1998, 17:857–872.
18. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM: The diagnostic odds
ratio: a single indicator of test performance. J Clin Epidemiol 2003,
56:1129–1135.
19. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A,
Tashiro K, Shimizu S: Molecular cloning and expression of human
hepatocyte growth factor. Nature 1989, 342:440–443.
20. Aoun E, Chen J, Reighard D, Gleeson FC, Whitcomb DC, Papachristou GI:
Diagnostic accuracy of interleukin-6 and interleukin-8 in predicting
severe acute pancreatitis: a meta-analysis. Pancreatology 2009, 9:777–785.
21. Ueda T, Takeyama Y, Toyokawa A, Kishida S, Yamamoto M, Saitoh Y:
Significant elevation of serum human hepatocyte growth factor levels in
patients with acute pancreatitis. Pancreas 1996, 12:76–83.
22. Espinosa L, Linares PM, Bejerano A, Lopez C, Sanchez A, Moreno-Otero R,
Gisbert JP: Soluble angiogenic factors in patients with acute pancreatitis.
J Clin Gastroenterol 2011, 45:630–637.
23. Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP,
McKay C, Toh SK, Skaife P, Leeder PC, Wilson P, Larvin M, Curtis LD: Double
blind, randomised, placebo controlled study of a platelet activating
factor antagonist, lexipafant, in the treatment and prevention of organ
failure in predicted severe acute pancreatitis. Gut 2001, 48:62–69.
24. Harrison DA, D’Amico G, Singer M: Case mix, outcome, and activity for
admissions to UK critical care units with severe acute pancreatitis: a
secondary analysis of the ICNARC Case Mix Programme Database.
Crit Care 2007, 11:S1.
25. Wu BU, Conwell DL: Update in acute pancreatitis. Curr Gastroenterol Rep
2010, 12:83–90.
26. Oiva J, Mustonen H, Kylänpää ML, Kyhälä L, Kuuliala K, Siitonen S,
Kemppainen E, Puolakkainen P, Repo H: Acute pancreatitis with organ
dysfunction associates with abnormal blood lymphocyte signaling:
controlled laboratory study. Crit Care 2010, 14:R207.
27. Chakraborty S, Kaur S, Muddana V, Sharma N, Wittel UA, Papachristou GI,
Whitcomb D, Brand RE, Batra SK: Elevated serum neutrophil gelatinase-
associated lipocalin is an early predictor of severity and outcome in
acute pancreatitis. Am J Gastroenterol 2010, 105:2050–2059.
28. Yilmaz G, Köksal I, Karahan SC, Mentese A: The diagnostic and prognostic
significance of soluble urokinase plasminogen activator receptor in
systemic inflammatory response syndrome. Clin Biochem 2011,
44:1227–1230.
29. Moore DJ, Greystoke A, Butt F, Wurthner J, Growcott J, Hughes A, Dive C:
A pilot study assessing the prognostic value of CK18 and nDNA
biomarkers in severe sepsis patients. Clin Drug Investig 2012, 32:179–187.
30. Oiva J, Mustonen H, Kylänpää ML, Kuuliala K, Siitonen S, Kemppainen E,
Puolakkainen P, Repo H: Patients with acute pancreatitis complicated byorgan dysfunction show abnormal peripheral blood polymorphonuclear
leukocyte signaling. Pancreatology 2013, 13:118–124.
31. Skibsted S, Bhasin MK, Aird WC, Shapiro NI: Bench-to-bedside review: future
novel diagnostics for sepsis—a systems biology approach. Crit Care 2013,
17:231.
32. Kylänpää-Bäck ML, Takala A, Kemppainen E, Puolakkainen P, Kautiainen H,
Jansson SE, Haapiainen R, Repo H: Cellular markers of systemic inflammation
and immune suppression in patients with organ failure due to severe
acute pancreatitis. Scand J Gastroenterol 2001, 36:1100–1107.
33. Cavaillon JM, Annane D: Compartmentalization of the inflammatory
response in sepsis and SIRS. J Endotoxin Res 2006, 12:151–170.
34. Caldwell CC, Hotchkiss RS: The first step in utilizing immune-modulating
therapies: immune status determination. Crit Care 2011, 15:108.
doi:10.1186/cc13885
Cite this article as: Nieminen et al.: Circulating cytokines in predicting
development of severe acute pancreatitis. Critical Care 2014 18:R104.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
